MK 801 reverses haloperidol-induced catalepsy from both stratial and extrastratial sites in the rat brain

European Journal of Pharmacology

Volumn 332, Issue 2, 1997, Pages 153-160

  Kaur, Simranjit ^a   Özer, Hülya ^a   Starr, Michael ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Catalepsy; Haloperidol; MK 801; Muscimol

Indexed keywords

DIZOCILPINE; HALOPERIDOL; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENTOPEDUNCULAR NUCLEUS; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLOBUS PALLIDUS; HALOPERIDOL; MALE; MUSCIMOL; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; THALAMUS;

EID: 18544391840     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01078-9     Document Type: Article

References (39)

1. Albin, R.L., Young, P.A.B., 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
2. Albin, R.L., Makowiec, R.L., Hollingsworth, Z.R., Dure, L.S., Penney, J.B., Young, A.B., 1992. Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study. Neuroscience 46, 35-48.
3. Blandini, F., Greenamyre, J.T., Nappi, G., 1996. The role of glutamate in the pathophysiology of Parkinson's disease. Funct. Neurol. 11, 3-15.
4. Danysz, W., Gossel, M., Zajaczkowski, W., Dill, D., Quack, G., 1994. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural Transm. 7, 155-166.
5. Ellenbroek, B., Schwarcz, M., Sontag, K.-H., Jaspers, R., Cools, A., 1985. Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: Tonic EMG activity in rats. Brain Res. 345, 132-140.
6. Elliott, P.J., Close, S.P., Walsh, D.M., Hayes, A.G., Marriott, A.S., 1990. Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J. Neural Transm. 2 (P.D. Sect.), 91-100.
7. Gerfen, C.R., 1992. The neostriatal mosaic: Multiple levels of compartmental organization. Trends Neurosci. 15, 133-139.
8. Greenamyre, J.T., 1993. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transm. 91, 255-269.
9. Greenamyre, J.T., O'Brien, C.F., 1991. N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48, 977-981.
10. Hauber, W., Schmidt, W.J., 1990. The NMDA antagonist dizocilpine (MK-801) reverses haloperidol-induced movement initiation deficits. Behav. Brain Res. 41, 161-166.
11. Kaur, S., Starr, M.S., 1997. Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat. Neuroscience 76, 345-354.
12. Klockgether, T., Turski, L., 1989. Excitatory amino acids and the basal ganglia: Implications for the therapy of Parkinson's disease. Trends Neurosci. 12, 285-286.
13. Klockgether, T., Turski, L., 1990. NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28, 539-546.
14. Klockgether, T., Turski, L., Löschmann, P.-A., Wachtel, H., 1990. N-Methyl-D-aspartate antagonists stimulate locomotor activity in monoamine-depleted rats: Implications for the therapy of Parkinson's disease. In: Lubec, G., Rosenthal, G.A. (Eds.), Amino Acids: Chemistry, Biology and Medicine. ESCOM, Leiden, pp. 269-275.
15. Klockgether, T., Löschmann, P.-A., Wüllner, U., 1994. New medical and surgical treatments for Parkinson's disease. Curr. Opin. Neurol. 7, 346-352.
16. Kornhuber, J., Weller, M., Riederer, P., 1993. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J. Neural. Transm. 6 (P.D. Sect.), 63-72.
17. Levy, R., Hazrati, L.-N., Herrero, M.-T., Vila, M., Hassani, O.-K., Mouroux, M., Ruberg, M., Aseni, H., Agid, Y., Féger, J., Obeso, J.A., Parent, A., Hirsch, E.C., 1997. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 76, 335-343.
18. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J.-F., Broussolle, E., Perret, J.E., Benabid, A.-L., 1995. Effect on Parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345, 91-95.
19. Löschmann, P.-A., Lange, K.W., Kunow, M., Rettig, K.-J., Jähnig, P., Honoré, T., Turski, L., Wachtel, H., Jenner, P., Marsden, C.D., 1991. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J. Neural Transm. 3, 203-213.
20. Lozano, A.M., Lang, A.E., Galvez-Jimenez, N., Miyasaki, J., Duff, J., Hutchinson, W.D., Dostrovsky, J.O., 1995. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 346, 1383-1387.
21. Mehta, A., Ticku, M.K., 1990. Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci. 46, 37-42.
22. Morelli, M., Di Chiara, G., 1985. Catalepsy induced by SCH 23390 in rats. Eur. J. Pharmacol. 117, 179-185.
23. Ossowska, K., 1994. The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural Transm. 8 (P.D. Sect.), 39-71.
24. 9 dopamine receptors in neuroleptic catalepsy. Eur. J. Pharmacol. 182, 327-334.
25. Papa, S.M., Engber, T.M., Boldry, R.C., Chase, T.N., 1993. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur. J. Pharmacol. 232, 247-253.
26. Paxinos, G., Watson, C., 1986. The Rat Brain Stereotaxic Atlas. Academic Press, Sydney.
27. 3H]MK-304 binding in rat brain. J. Neurochem. 60, 1344-1353.
28. Scheel-Krüger, J., Magelund, G., Olianas, M.C., 1981. Role of GABA in the striatal output system: Globus pallidus, nucleus entopeduncularis, substantia nigra and nucleus subthalamicus. In: Di Chiara, G., Gessa, G.L. (Eds.), GABA and the Basal Ganglia. Raven Press, New York, NY, pp. 165-186.
29. Schmidt, W.J., 1986. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 90, 123-130.
30. Schmidt, W.J., Bubser, M., Hauber, W., 1992. Behavioural pharmacology of glutamate in the basal ganglia. J. Neural Transm. 38 (Suppl.), 65-89.
31. Schuster, G., 1990. AP-5 injected into the medial substantia nigra pars reticulata induces stereotyped behaviour. In: Elsner, N., Roth, G. (Eds.), Brain: Perception, Cognition. Thieme, Stuttgart, pp. 499-506.
32. Standaert, D.G., Testa, C.M., Young, A.B., Penney, J.B., 1994. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343, 1-16.
33. Starr, M.S., 1995a. Antiparkinsonian actions of glutamate antagonists, alone and with L-DOPA: A review of evidence and suggestions for possible mechanisms. J. Neural Transm. 10 (P.D. Sect.), 141-185.
34. 9 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19, 264-293.
35. Starr, M.S., Summerhayes, M., 1983. Role of the ventromedial nucleus of the thalamus in motor behaviour. I. Effects of focal injections of drugs. Neuroscience 10, 1157-1169.
36. St-Pierre, J.A., Bédard, P.-J., 1994. Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model. Brain Res. 660, 255-260.
37. 2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 109, 477-483.
38. Yoshida, Y., Ono, T., Kizu, A., Fukushima, R., Miyagashi, T., 1991. Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur. J. Pharmacol. 203, 173-180.
39. Yoshida, Y., Ono, T., Kawano, K., Miyagashi, T., 1994. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate- putamen. Brain Res. 639, 139-148.